Udayavni Special

FDA withdraws emergency use authorization of chloroquine and hydroxychloroquine


PTI, Jun 16, 2020, 8:05 AM IST

Washington: The US food and drug regulatory body on Monday, June 15 withdrew the emergency use authorization of anti-malarial drugs chloroquine and hydroxychloroquine in the treatment of COVID-19 patients after concluding that they may not be effective to cure the virus infections.

The Food and Drug Administration (FDA) said its decision is based on new information, including clinical trial data results, that have led it to conclude that the drugs may not be effective to treat COVID-19 and that its potential benefits for such use do not outweigh its known and potential risks.

FDA chief scientist Denise Hinton, in a letter dated June 15 to Gary Disbrow of Biomedical Advanced Research and Development Authority (BARDA), said as of the date of this letter, the oral formulations of hydroxychloroquine (HCQ) and (chloroquine) CQ are no longer authorized by the FDA to treat COVID-19.

On March 28, FDA had issued emergency use authorization (EUA) for use of oral formulations of chloroquine phosphate (CQ) and hydroxychloroquine sulfate (HCQ) to be distributed from the Strategic National Stockpile (SNS).

Hinton said that FDA now believes that the suggested dosing regimens for CQ and HCQ are unlikely to produce an antiviral effect.

“Earlier observations of decreased viral shedding with HCQ or CQ treatment have not been consistently replicated and recent data from a randomized controlled trial assessing probability of negative conversion showed no difference between HCQ and standard of care alone,” he said.

Current US treatment guidelines do not recommend the use of CQ or HCQ in hospitalized patients with COVID-19 outside of a clinical trial, and the NIH guidelines now recommend against such use outside of a clinical trial, the FDA said.

“Recent data from a large randomized controlled trial showed no evidence of benefit for mortality or other outcomes such as hospital length of stay or need for mechanical ventilation of HCQ treatment in hospitalised patients with COVID-19,” the letter said.

Hinton said that while HCQ, that has been distributed from SNS, is no longer authorized under the EUA to treat hospitalized patients for COVID-19, FDA-approved HCQ can be distributed in interstate commerce.

Hydroxychloroquine is one of the oldest and best-known anti-malarial drugs. US President Donald Trump had called hydroxychloroquine a “game-changer” drug in the fight against COVID-19.

At Trump’s request, India in April allowed the export of 50 million HCQ tablets to treat COVID-19 patients in America, the worst-hit country by the pandemic.

Trump had on May 18 disclosed that he was taking hydroxychloroquine daily to ward off the deadly coronavirus.

Defending the drug, he had said that hydroxychloroquine was a “line of defense” against the coronavirus.

“It is a very powerful drug I guess but it doesn’t harm you and so I thought as a frontline defense, possibly it would be good, and I have had no impact from it,” Trump had said, adding that the antimalaria drug has received tremendous reviews from doctors all over the world.

According to the Johns Hopkins University data, US has over 2.1 million COVID-19 cases with more than 115,000 deaths.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Number of people vaccinated against COVID-19 more than double number of active cases says Govt

Ullal: Awareness campaign organised against waste disposal on Netravati bridge

Indian military team to leave for Russia soon to train on operational aspects of S-400 missiles

Pant surpasses Dhoni to become fastest Indian stumper to reach 1000 runs in Test cricket

Govt declares Subhas Chandra Bose birth anniversary as Parakram Diwas

‘Surprise party’: Beer truck topples in K’taka, locals grab bottles

Number of people vaccinated against COVID-19 more than double number of active cases:Govt


Related Articles More

‘Do not take antidote if…’: Bharat Biotech says in fact sheet on Covaxin

53,341 frontline workers in Karnataka vaccinated so far

Sandur man died of heart attack not from COVID-19 vaccine says K Sudhakar

3.81 lakhs received COVID-19 vaccine, 580 adverse events reported says Health Ministry

COVID-19: India records lowest fatalities in eight months

MUST WATCH

Arnab-Gupta WhatsApp chat leak!! New story, much misery…

‘Act of revenge’: Attack on constable Ganesh Kamath was to avenge M’luru police firing

Udayavani Campaign: Identify parking areas to resolve public problems , says MLA Kamath

Chief Minister Yeddyurappa visits Uchila Mahalakshmi Temple

Cow Giving Birth – First Time Milking After Cow Delivery

Latest Additions

Number of people vaccinated against COVID-19 more than double number of active cases says Govt

Ullal: Tipper truck-car collision; 2 severely injured

IISc’s Centre for Networking Intelligence gets new state- of-the-art networking lab

Ullal: Awareness campaign organised against waste disposal on Netravati bridge

India, the land of mysteries: Haunted places in Karnataka

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.